Annual EBITDA
-$103.79 M
+$72.87 M+41.25%
31 December 2023
Summary:
Heron Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$103.79 million, with the most recent change of +$72.87 million (+41.25%) on 31 December 2023. During the last 3 years, it has risen by +$118.74 million (+53.36%). HRTX annual EBITDA is now -12874.00% below its all-time high of -$800.00 thousand, reached on 31 December 1997.HRTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$3.88 M
+$1.93 M+33.20%
30 September 2024
Summary:
Heron Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$3.88 million, with the most recent change of +$1.93 million (+33.20%) on 30 September 2024. Over the past year, it has increased by +$20.32 million (+83.98%). HRTX quarterly EBITDA is now -467.14% below its all-time high of $1.06 million, reached on 31 December 2010.HRTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$19.37 M
+$20.32 M+51.20%
30 September 2024
Summary:
Heron Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$19.37 million, with the most recent change of +$20.32 million (+51.20%) on 30 September 2024. Over the past year, it has increased by +$103.30 million (+84.21%). HRTX TTM EBITDA is now -2037.10% below its all-time high of $1.00 million, reached on 30 September 1987.HRTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HRTX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +41.3% | +84.0% | +84.2% |
| 3 y3 years | +53.4% | +92.4% | +91.2% |
| 5 y5 years | +40.6% | +88.7% | +90.0% |
HRTX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +53.4% | at high | +93.8% | at high | +91.4% |
| 5 y | 5 years | at high | +53.4% | at high | +93.8% | at high | +91.5% |
| alltime | all time | <-9999.0% | +53.4% | -467.1% | +94.0% | -2037.1% | +91.5% |
Heron Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.88 M(-33.2%) | -$19.37 M(-51.2%) |
| June 2024 | - | -$5.80 M(+41.3%) | -$39.70 M(-47.5%) |
| Mar 2024 | - | -$4.11 M(-26.4%) | -$75.56 M(-27.2%) |
| Dec 2023 | -$103.79 M(-41.2%) | -$5.58 M(-76.9%) | -$103.79 M(-15.4%) |
| Sept 2023 | - | -$24.20 M(-41.9%) | -$122.67 M(-12.2%) |
| June 2023 | - | -$41.66 M(+28.8%) | -$139.64 M(-4.9%) |
| Mar 2023 | - | -$32.34 M(+32.3%) | -$146.80 M(-16.9%) |
| Dec 2022 | -$176.66 M(-17.9%) | -$24.46 M(-40.6%) | -$176.66 M(-14.0%) |
| Sept 2022 | - | -$41.18 M(-15.7%) | -$205.39 M(-4.5%) |
| June 2022 | - | -$48.83 M(-21.5%) | -$215.17 M(-4.8%) |
| Mar 2022 | - | -$62.20 M(+16.9%) | -$226.08 M(+5.0%) |
| Dec 2021 | -$215.25 M(-3.3%) | -$53.19 M(+4.4%) | -$215.25 M(-2.1%) |
| Sept 2021 | - | -$50.95 M(-14.7%) | -$219.86 M(-2.9%) |
| June 2021 | - | -$59.73 M(+16.3%) | -$226.52 M(+2.1%) |
| Mar 2021 | - | -$51.38 M(-11.1%) | -$221.79 M(-0.3%) |
| Dec 2020 | -$222.53 M(+10.6%) | -$57.80 M(+0.3%) | -$222.53 M(+3.0%) |
| Sept 2020 | - | -$57.62 M(+4.7%) | -$216.11 M(+12.1%) |
| June 2020 | - | -$55.00 M(+5.5%) | -$192.83 M(+2.0%) |
| Mar 2020 | - | -$52.11 M(+1.4%) | -$189.11 M(-6.0%) |
| Dec 2019 | -$201.23 M(+15.2%) | -$51.38 M(+49.7%) | -$201.23 M(+4.3%) |
| Sept 2019 | - | -$34.33 M(-33.1%) | -$192.98 M(-3.5%) |
| June 2019 | - | -$51.29 M(-20.2%) | -$200.04 M(+6.8%) |
| Mar 2019 | - | -$64.23 M(+48.9%) | -$187.28 M(+7.2%) |
| Dec 2018 | -$174.66 M(-9.0%) | -$43.13 M(+4.2%) | -$174.66 M(-9.0%) |
| Sept 2018 | - | -$41.40 M(+7.5%) | -$192.02 M(+0.3%) |
| June 2018 | - | -$38.52 M(-25.4%) | -$191.53 M(-1.6%) |
| Mar 2018 | - | -$51.61 M(-14.7%) | -$194.66 M(+1.4%) |
| Dec 2017 | -$192.02 M(+13.4%) | -$60.49 M(+47.9%) | -$192.02 M(+8.1%) |
| Sept 2017 | - | -$40.91 M(-1.8%) | -$177.58 M(-3.5%) |
| June 2017 | - | -$41.64 M(-15.0%) | -$184.10 M(-0.6%) |
| Mar 2017 | - | -$48.97 M(+6.3%) | -$185.28 M(+9.4%) |
| Dec 2016 | -$169.38 M(+76.6%) | -$46.06 M(-2.9%) | -$169.38 M(+10.1%) |
| Sept 2016 | - | -$47.43 M(+10.8%) | -$153.85 M(+19.5%) |
| June 2016 | - | -$42.81 M(+29.5%) | -$128.74 M(+18.4%) |
| Mar 2016 | - | -$33.07 M(+8.3%) | -$108.77 M(+13.4%) |
| Dec 2015 | -$95.90 M(+28.0%) | -$30.53 M(+36.8%) | -$95.90 M(+12.0%) |
| Sept 2015 | - | -$22.32 M(-2.3%) | -$85.59 M(+4.3%) |
| June 2015 | - | -$22.84 M(+13.0%) | -$82.08 M(+5.4%) |
| Mar 2015 | - | -$20.21 M(-0.1%) | -$77.90 M(+4.0%) |
| Dec 2014 | -$74.90 M(+38.4%) | -$20.23 M(+7.6%) | -$74.90 M(+9.5%) |
| Sept 2014 | - | -$18.80 M(+0.7%) | -$68.41 M(+10.0%) |
| June 2014 | - | -$18.67 M(+8.5%) | -$62.18 M(+6.0%) |
| Mar 2014 | - | -$17.21 M(+25.3%) | -$58.65 M(+8.4%) |
| Dec 2013 | -$54.12 M(+129.1%) | -$13.73 M(+9.2%) | -$54.12 M(+10.5%) |
| Sept 2013 | - | -$12.58 M(-16.9%) | -$48.96 M(+15.5%) |
| June 2013 | - | -$15.13 M(+19.3%) | -$42.38 M(+34.2%) |
| Mar 2013 | - | -$12.68 M(+47.9%) | -$31.59 M(+33.7%) |
| Dec 2012 | -$23.63 M(+117.1%) | -$8.57 M(+42.8%) | -$23.63 M(+23.5%) |
| Sept 2012 | - | -$6.00 M(+38.4%) | -$19.13 M(+11.4%) |
| June 2012 | - | -$4.34 M(-8.1%) | -$17.18 M(+19.8%) |
| Mar 2012 | - | -$4.72 M(+15.8%) | -$14.33 M(+31.7%) |
| Dec 2011 | -$10.88 M(+56.2%) | -$4.08 M(+0.7%) | -$10.88 M(+89.2%) |
| Sept 2011 | - | -$4.05 M(+170.8%) | -$5.75 M(+75.1%) |
| June 2011 | - | -$1.49 M(+17.9%) | -$3.29 M(-39.5%) |
| Mar 2011 | - | -$1.27 M(-220.0%) | -$5.43 M(-22.1%) |
| Dec 2010 | -$6.97 M(-29.5%) | $1.06 M(-166.8%) | -$6.97 M(-30.6%) |
| Sept 2010 | - | -$1.58 M(-56.6%) | -$10.04 M(+4.7%) |
| June 2010 | - | -$3.64 M(+29.8%) | -$9.58 M(-2.4%) |
| Mar 2010 | - | -$2.80 M(+39.2%) | -$9.82 M(-0.7%) |
| Dec 2009 | -$9.89 M(-57.1%) | -$2.01 M(+79.0%) | -$9.89 M(-14.8%) |
| Sept 2009 | - | -$1.13 M(-71.0%) | -$11.60 M(-30.3%) |
| June 2009 | - | -$3.87 M(+34.8%) | -$16.65 M(-12.0%) |
| Mar 2009 | - | -$2.87 M(-22.9%) | -$18.92 M(-17.9%) |
| Dec 2008 | -$23.03 M(-1.3%) | -$3.73 M(-39.6%) | -$23.03 M(-14.8%) |
| Sept 2008 | - | -$6.17 M(+0.5%) | -$27.03 M(+3.6%) |
| June 2008 | - | -$6.14 M(-12.1%) | -$26.10 M(+8.8%) |
| Mar 2008 | - | -$6.99 M(-9.6%) | -$23.98 M(+4.0%) |
| Dec 2007 | -$23.34 M(+23.7%) | -$7.73 M(+47.6%) | -$23.07 M(+9.5%) |
| Sept 2007 | - | -$5.24 M(+30.1%) | -$21.06 M(+7.0%) |
| June 2007 | - | -$4.03 M(-33.8%) | -$19.69 M(-3.3%) |
| Mar 2007 | - | -$6.08 M(+6.1%) | -$20.36 M(+9.5%) |
| Dec 2006 | -$18.86 M(+135.0%) | -$5.73 M(+48.3%) | -$18.59 M(+22.0%) |
| Sept 2006 | - | -$3.86 M(-17.8%) | -$15.24 M(+15.3%) |
| June 2006 | - | -$4.70 M(+9.1%) | -$13.21 M(+19.6%) |
| Mar 2006 | - | -$4.30 M(+81.1%) | -$11.05 M(+39.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2005 | -$8.03 M(-7.6%) | -$2.38 M(+29.4%) | -$7.94 M(+6.0%) |
| Sept 2005 | - | -$1.84 M(-27.3%) | -$7.49 M(-0.6%) |
| June 2005 | - | -$2.53 M(+110.3%) | -$7.54 M(+2.5%) |
| Mar 2005 | - | -$1.20 M(-37.6%) | -$7.36 M(-15.3%) |
| Dec 2004 | -$8.69 M(+45.8%) | -$1.93 M(+2.2%) | -$8.69 M(+8.4%) |
| Sept 2004 | - | -$1.88 M(-19.7%) | -$8.01 M(+11.1%) |
| June 2004 | - | -$2.35 M(-7.3%) | -$7.21 M(+7.5%) |
| Mar 2004 | - | -$2.53 M(+102.4%) | -$6.71 M(+12.6%) |
| Dec 2003 | -$5.96 M(+30.1%) | -$1.25 M(+15.2%) | -$5.96 M(+13.7%) |
| Sept 2003 | - | -$1.08 M(-41.1%) | -$5.24 M(-6.3%) |
| June 2003 | - | -$1.84 M(+3.5%) | -$5.59 M(+6.2%) |
| Mar 2003 | - | -$1.78 M(+234.0%) | -$5.26 M(+12.6%) |
| Dec 2002 | -$4.58 M(-32.3%) | -$533.00 K(-62.9%) | -$4.68 M(-30.3%) |
| Sept 2002 | - | -$1.44 M(-5.0%) | -$6.71 M(-6.9%) |
| June 2002 | - | -$1.51 M(+27.0%) | -$7.20 M(-0.1%) |
| Mar 2002 | - | -$1.19 M(-53.5%) | -$7.21 M(-1.7%) |
| Dec 2001 | -$6.77 M(+67.8%) | -$2.56 M(+32.6%) | -$7.33 M(+12.4%) |
| Sept 2001 | - | -$1.93 M(+27.0%) | -$6.52 M(+19.0%) |
| June 2001 | - | -$1.52 M(+15.8%) | -$5.48 M(+10.2%) |
| Mar 2001 | - | -$1.31 M(-25.1%) | -$4.97 M(+13.7%) |
| Dec 2000 | -$4.03 M(+168.9%) | -$1.75 M(+96.6%) | -$4.38 M(+33.2%) |
| Sept 2000 | - | -$892.00 K(-12.0%) | -$3.29 M(+6.9%) |
| June 2000 | - | -$1.01 M(+41.6%) | -$3.07 M(+110.5%) |
| Mar 2000 | - | -$716.10 K(+7.8%) | -$1.46 M(-1036.0%) |
| Dec 1999 | -$1.50 M(-25.0%) | -$664.50 K(-2.2%) | $156.00 K(-106.3%) |
| Sept 1999 | - | -$679.50 K(-213.2%) | -$2.48 M(+125.4%) |
| June 1999 | - | $600.00 K(-33.3%) | -$1.10 M(+10.0%) |
| Mar 1999 | - | $900.00 K(-127.3%) | -$1.00 M(-23.1%) |
| Dec 1998 | -$2.00 M(+150.0%) | -$3.30 M(-571.4%) | -$1.30 M(-425.0%) |
| Sept 1998 | - | $700.00 K(0.0%) | $400.00 K(-200.0%) |
| June 1998 | - | $700.00 K(+16.7%) | -$400.00 K(-69.2%) |
| Mar 1998 | - | $600.00 K(-137.5%) | -$1.30 M(+30.0%) |
| Dec 1997 | -$800.00 K(-88.7%) | -$1.60 M(+1500.0%) | -$1.00 M(-56.5%) |
| Sept 1997 | - | -$100.00 K(-50.0%) | -$2.30 M(-37.8%) |
| June 1997 | - | -$200.00 K(-122.2%) | -$3.70 M(-24.5%) |
| Mar 1997 | - | $900.00 K(-131.0%) | -$4.90 M(-31.0%) |
| Dec 1996 | -$7.10 M(-4.1%) | -$2.90 M(+93.3%) | -$7.10 M(-2.7%) |
| Sept 1996 | - | -$1.50 M(+7.1%) | -$7.30 M(-3.9%) |
| June 1996 | - | -$1.40 M(+7.7%) | -$7.60 M(-3.8%) |
| Mar 1996 | - | -$1.30 M(-58.1%) | -$7.90 M(+9.7%) |
| Dec 1995 | -$7.40 M(-6.3%) | -$3.10 M(+72.2%) | -$7.20 M(+30.9%) |
| Sept 1995 | - | -$1.80 M(+5.9%) | -$5.50 M(-14.1%) |
| June 1995 | - | -$1.70 M(+183.3%) | -$6.40 M(-11.1%) |
| Mar 1995 | - | -$600.00 K(-57.1%) | -$7.20 M(-12.2%) |
| Dec 1994 | -$7.90 M(-14.1%) | -$1.40 M(-48.1%) | -$8.20 M(-11.8%) |
| Sept 1994 | - | -$2.70 M(+8.0%) | -$9.30 M(+3.3%) |
| June 1994 | - | -$2.50 M(+56.3%) | -$9.00 M(-1.1%) |
| Mar 1994 | - | -$1.60 M(-36.0%) | -$9.10 M(-3.2%) |
| Dec 1993 | -$9.20 M(+73.6%) | -$2.50 M(+4.2%) | -$9.40 M(+6.8%) |
| Sept 1993 | - | -$2.40 M(-7.7%) | -$8.80 M(+23.9%) |
| June 1993 | - | -$2.60 M(+36.8%) | -$7.10 M(+34.0%) |
| Mar 1993 | - | -$1.90 M(0.0%) | -$5.30 M(0.0%) |
| Dec 1992 | -$5.30 M(+65.6%) | -$1.90 M(+171.4%) | -$5.30 M(+17.8%) |
| Sept 1992 | - | -$700.00 K(-12.5%) | -$4.50 M(-6.3%) |
| June 1992 | - | -$800.00 K(-57.9%) | -$4.80 M(+14.3%) |
| Mar 1992 | - | -$1.90 M(+72.7%) | -$4.20 M(+27.3%) |
| Dec 1991 | -$3.20 M(-17.9%) | -$1.10 M(+10.0%) | -$3.30 M(+3.1%) |
| Sept 1991 | - | -$1.00 M(+400.0%) | -$3.20 M(-3.0%) |
| June 1991 | - | -$200.00 K(-80.0%) | -$3.30 M(-17.5%) |
| Mar 1991 | - | -$1.00 M(0.0%) | -$4.00 M(+5.3%) |
| Dec 1990 | -$3.90 M(-15.2%) | -$1.00 M(-9.1%) | -$3.80 M(-2.6%) |
| Sept 1990 | - | -$1.10 M(+22.2%) | -$3.90 M(+5.4%) |
| June 1990 | - | -$900.00 K(+12.5%) | -$3.70 M(-2.6%) |
| Mar 1990 | - | -$800.00 K(-27.3%) | -$3.80 M(+52.0%) |
| Dec 1989 | -$4.60 M(-8.0%) | -$1.10 M(+22.2%) | -$2.50 M(-73.1%) |
| Sept 1989 | - | -$900.00 K(-10.0%) | -$9.30 M(+19.2%) |
| June 1989 | - | -$1.00 M(-300.0%) | -$7.80 M(+23.8%) |
| Mar 1989 | - | $500.00 K(-106.3%) | -$6.30 M(+6.8%) |
| Dec 1988 | -$5.00 M(+56.3%) | -$7.90 M(-1416.7%) | -$5.90 M(+90.3%) |
| Sept 1988 | - | $600.00 K(+20.0%) | -$3.10 M(-8.8%) |
| June 1988 | - | $500.00 K(-44.4%) | -$3.40 M(-2.9%) |
| Mar 1988 | - | $900.00 K(-117.6%) | -$3.50 M(-14.6%) |
| Dec 1987 | -$3.20 M | -$5.10 M(-1800.0%) | -$4.10 M(-510.0%) |
| Sept 1987 | - | $300.00 K(-25.0%) | $1.00 M(+42.9%) |
| June 1987 | - | $400.00 K(+33.3%) | $700.00 K(+133.3%) |
| Mar 1987 | - | $300.00 K | $300.00 K |
FAQ
- What is Heron Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Heron Therapeutics?
- What is Heron Therapeutics annual EBITDA year-on-year change?
- What is Heron Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Heron Therapeutics?
- What is Heron Therapeutics quarterly EBITDA year-on-year change?
- What is Heron Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Heron Therapeutics?
- What is Heron Therapeutics TTM EBITDA year-on-year change?
What is Heron Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of HRTX is -$103.79 M
What is the all time high annual EBITDA for Heron Therapeutics?
Heron Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$800.00 K
What is Heron Therapeutics annual EBITDA year-on-year change?
Over the past year, HRTX annual earnings before interest, taxes, depreciation & amortization has changed by +$72.87 M (+41.25%)
What is Heron Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of HRTX is -$3.88 M
What is the all time high quarterly EBITDA for Heron Therapeutics?
Heron Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $1.06 M
What is Heron Therapeutics quarterly EBITDA year-on-year change?
Over the past year, HRTX quarterly earnings before interest, taxes, depreciation & amortization has changed by +$20.32 M (+83.98%)
What is Heron Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of HRTX is -$19.37 M
What is the all time high TTM EBITDA for Heron Therapeutics?
Heron Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $1.00 M
What is Heron Therapeutics TTM EBITDA year-on-year change?
Over the past year, HRTX TTM earnings before interest, taxes, depreciation & amortization has changed by +$103.30 M (+84.21%)